In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 1, 2002, Pages 36-46

  Li, Y ^a   Tian, Z ^a,b   Rizvi, S M A ^a,c   Bander, N H ^d   Allen, B J ^a,c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIBODY CONJUGATE; BISMUTH 213; KI 67 ANTIGEN; METHOXYFLURANE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; LINEAR ENERGY TRANSFER; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; TUMOR VOLUME; TUMOR XENOGRAFT;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; APOPTOSIS; BISMUTH; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOCONJUGATES; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 85047699075     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500543     Document Type: Article

References (65)

1. Cancer statistics
2. Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center
3. A structural literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team
4. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993
5. The influence of hormonal therapy on survival of men with advanced prostatic cancer
6. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate
7. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149
8. The specific inhibition of cellular clonogenic proliferation using 211At labeled lectins and antibodies-1
9. Cellular dosimetry: Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments
10. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy
11. 211At radiocolloid therapy: Further observations and comparison with radiocolloids of 32P, 165Dy, 90Y
12. Radioimmunotherapy with alpha-particle-emitting immunoconjugates
13. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro
14. Expression of the prostate-specific membrane antigen
15. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy
16. Prostate-specific membrane antigen expression in normal and malignant human tissues
17. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumour vascular endothelium
18. Constitutive and antibody-induced internalization of prostate-specific membrane antigen
19. Preclinical models of prostate cancer
20. Isolation of a human prostate carcinoma cell line (DU 145)
21. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
22. LNCaP model of human prostatic carcinoma
23. Selection of highly metastatic variants of different human prostatic carcinomas using orthopotic implantation in nude mice
24. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP
25. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
26. Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer
27. Radio-immunoconjugates for targeted alpha therapy of malignant melanoma
28. Preclinical targeted alpha therapy for melanoma
29. In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes
30. In vitro and preclinical studies of targeted alpha therapy for colorectal cancer
31. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers
32. 213Bi]J591 for radioimmunotherapy of prostate cancer
33. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
34. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
35. In situ apoptotic cell labeling by the TUNEL method: Improvement and evaluation on cell preparation
36. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice
37. Role of basement membrane and laminin in metastases and tumour growth
38. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts
39. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
40. Phase 1 trial of targeted α-particle therapy for myeloid leukaemias with bismuth-213-HuM195 (anti-CD33)
41. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac
42. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
43. Radioimmunotherapy with alpha-particle-emitting radioimmunoconjugates
44. Targeted therapy using alpha emitters
45. Radioimmunotherapy with alpha-emitting nuclides
46. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia
47. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate
48. 213Bi
49. In vitro and in vivo reactivity of anti-prostate monoclonal antibody immunoconjugate 7E11. C5.3-GYK-DTPA
50. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5
51. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization
52. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumour-associated neovasculature
53. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)
54. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
55. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
56. Apoptosis in cancer therapy: Crossing the threshold
57. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6
58. P53-Dependent apoptosis suppresses tumour growth and progression in vivo
59. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after x-irradiation of mammalian cells
60. DNA damage produced by ionizing radiation in mammalian cells: Identifies, mechanisms of information, reparability
61. Sublethal damage, potentially lethal damage, and chromosomal aberrations in mammalian cells exposed to ionizing radiation
62. Radiation-induced apoptosis in a murine T-cell hybridoma
63. Change in the frequency of apoptosis after low- and high-dose X-irradiation of human lymphocytes
64. Tumour necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis
65. Sphingosine enhances apoptosis of radiation resistant prostate cancer cells